Skip to Content

New Drug Approvals Archive - December 2017

December 2017

Repatha (evolocumab)

New Indication Approved: December 1, 2017
Treatment for: High Cholesterol; Prevention of Heart Attack and Stroke

Ogivri (trastuzumab-dkst)

Date of Approval: December 1, 2017
Company: Mylan GmbH
Treatment for: Breast Cancer, Stomach Cancer

Ogivri (trastuzumab-dkst) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer and the treatment of HER2-overexpressing stomach cancer.

Lonhala Magnair (glycopyrrolate) Inhalation Solution

Date of Approval: December 5, 2017
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Chronic Obstructive Pulmonary Disease

Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Ozempic (semaglutide) Injection

Date of Approval: December 5, 2017
Company: Novo Nordisk
Treatment for: Diabetes Type 2

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes.

Admelog (insulin lispro) Injection

Date of Approval: December 11, 2017
Company: Sanofi
Treatment for: Diabetes Type 1, Diabetes Type 2

Admelog (insulin lispro) is a follow-on rapid-acting human insulin analog (referenced to Humalog) for the treatment of patients with type 1 and type 2 diabetes.

Sinuva (mometasone furoate) Sinus Implant

Date of Approval: December 8, 2017
Company: Intersect ENT, Inc.
Treatment for: Nasal Polyps

Sinuva (mometasone furoate) is a corticosteroid-eluting sinus implant indicated for the treatment of recurrent nasal polyp disease.

Omidria (ketorolac and phenylephrine)

Patient Population Altered: December 12, 2017
Treatment for: Intraocular Lens Replacement Procedures

Ixifi (infliximab-qbtx) Injection

Date of Approval: December 13, 2017
Company: Pfizer Inc.
Treatment for: Crohn's Disease -- Maintenance, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis

Ixifi (infliximab-qbtx) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) indicated for the treatment of Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

Xepi (ozenoxacin) Cream

Date of Approval: December 11, 2017
Company: Medimetriks Pharmaceuticals, Inc.
Treatment for: Impetigo

Xepi (ozenoxacin) is a topical non-fluorinated quinolone for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Eskata (hydrogen peroxide) Topical Solution

Date of Approval: December 14, 2017
Company: Aclaris Therapeutics, Inc.
Treatment for: Seborrheic Keratoses

Eskata (hydrogen peroxide) 40% (w/w) topical solution is a high-concentration hydrogen peroxide formulation for the treatment of raised seborrheic keratoses.

Prexxartan (valsartan) Oral Solution

Date of Approval: December 19, 2017
Company: Medicure Inc.
Treatment for: Hypertension, Congestive Heart Failure, Left Ventricular Dysfunction

Prexxartan (valsartan) is an angiotensin II receptor blocker (ARB) oral solution formulation indicated for the treatment of hypertension, heart failure, and left ventricular dysfunction following myocardial infarction.

Rhopressa (netarsudil) Ophthalmic Solution

Date of Approval: December 18, 2017
Company: Aerie Pharmaceuticals, Inc.
Treatment for: Glaucoma

Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension.

Luxturna (voretigene neparvovec) Intraocular Suspension for Subretinal Injection

Date of Approval: December 19, 2017
Company: Spark Therapeutics
Treatment for: Biallelic RPE65-Mediated Inherited Retinal Disease

Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).

Macrilen (macimorelin) for Oral Solution

Date of Approval: December 20, 2017
Company: Aeterna Zentaris Inc.
Treatment for: Diagnosis of Adult Growth Hormone Deficiency

Macrilen (macimorelin) is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency.

Giapreza (angiotensin II) Injection - formerly LJPC-501

Date of Approval: December 21, 2017
Company: La Jolla Pharmaceutical Company
Treatment for: Hypotension, Shock

Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.

Steglatro (ertugliflozin) Tablets

Date of Approval: December 19, 2017
Company: Merck
Treatment for: Diabetes Type 2

Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to help improve glycemic control in adults with type 2 diabetes.

Steglujan (ertugliflozin and sitagliptin) Tablets

Date of Approval: December 19, 2017
Company: Merck & Co., Inc.
Treatment for: Diabetes Type 2

Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.

Segluromet (ertugliflozin and metformin hydrochloride) Tablets

Date of Approval: December 19, 2017
Company: Merck & Co., Inc.
Treatment for: Diabetes Type 2

Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.

Lumify (brimonidine tartrate) Ophthalmic Solution

Date of Approval: December 22, 2017
Company: Bausch + Lomb
Treatment for: Ocular Redness

Lumify (brimonidine tartrate) is an over-the-counter (OTC) formulation of the alpha-adrenergic agonist brimonidine indicated for use in the treatment of ocular redness.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.